|
Market Cap (24-Jun) $121,804,656 (1,258th) |
Close (30-Jun) $0.007 |
Volume (30-Jun) 188,484 |
Shortsold (14-May) 14,985,846 (0.14%) (426th) |
|
52w High $0.85 |
52w Low $0.350 |
P/E 10.33 |
EPS -0.08 |
ATH released this announcement to the ASX on 14 March 2023, 10:42. The announcement is marked as price sensitive, and is 3 page(s) in length and 202.1kb in size.
You can view all announcements from ATH and see how they appear on a price chart on the announcements page.
At the date of this announcement, ATH was 0.005% short sold according to ASIC data. It was ranked the 602nd most shorted stock on the ASX. It is now ranked as the 426th most shorted stock on the ASX with 0.138% of total shares short sold as of the latest reported data (14 May 2026).
| Other Recent Announcements from ATH | |
|---|---|
| Investor Presentation | 22 June 2023, 11:13 |
| ATH to present at MST Rare Diseases Rich Returns Forum | 21 June 2023, 9:52 |
| ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder | 30 May 2023, 13:32 |
| US patent grant and license agreement | 14 March 2023, 10:42 |
| Investor Webinar Presentation | 9 March 2023, 9:12 |
| First Patient Enrolled in Europe in Phase II Clinical trial | 8 March 2023, 9:19 |
| Half Yearly Report and Accounts | 28 February 2023, 13:18 |
You must be logged in to post a reply.
Alterity Therapeutics 